Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.615
-0.025 (-1.52%)
Mar 31, 2025, 2:31 PM EDT - Market open
Immuneering Employees
Immuneering had 68 employees as of December 31, 2023. The number of employees decreased by 5 or -6.85% compared to the previous year.
Employees
68
Change (1Y)
-5
Growth (1Y)
-6.85%
Revenue / Employee
n/a
Profits / Employee
-$897,597
Market Cap
57.96M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 68 | -5 | -6.85% |
Dec 31, 2022 | 73 | 9 | 14.06% |
Dec 31, 2021 | 64 | 38 | 146.15% |
Dec 31, 2020 | 26 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
IMRX News
- 9 days ago - Immuneering Corporation Announces Grant of Inducement Award - GlobeNewsWire
- 10 days ago - Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 11 days ago - Immuneering Names Dr. Igor Matushansky as Chief Medical Officer - GlobeNewsWire
- 7 weeks ago - Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - Why Is Immuneering Stock Trading Higher On Tuesday? - Benzinga
- 3 months ago - Immuneering Launches Pancreatic Cancer Advisory Board - GlobeNewsWire
- 3 months ago - Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? - Benzinga
- 3 months ago - Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma - GlobeNewsWire